Richard Conway
Tweet
Wittoek et al. 48-week RCT of Denosumab in erosive hand OA. Prevents structural progression! @RheumNow #ACR22 Abstr#L05 #ACRbest https://t.co/CI6VBERSmn https://t.co/OszJkGeJF7
All News
Eric Dein
Tweet
L05 #ACR22 High-dose Denosumab in Erosive Hand OA
48Wk, Double-blind PBO Phase 2 100 patients
GUSS change higher in DEN v PBO at w24, incr at w48
New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001)
Open label extension w improvement to baseline
@RheumNow https://t.co/X6MF9q2bKj
sheila
Tweet
This single ctr retrospective cohort study by AOhayn on antiRo/La+ moms show that the mean timing of first fetal echo for CHB screening was at 20wks AOG.
💠CHB+ in 3 fetuses on 1st echo (done 19, 22.4, 29.3 wks)
Take home msg? Do timely CHB screens
#ACR22 @RheumNow ABST#0957 https://t.co/59crW0uov4
Richard Conway
Tweet
Walrabenstein et al. RCT of 16-week triple intervention - plant-based diet, exercise, stress management - vs usual care in OA. It works, but we don't know which component, or if Hawthorn effect @RheumNow #ACR22 Abstr#1644 https://t.co/p74Ptd8bZ2 https://t.co/EOg7RxRmO7
Julian Segan
Tweet
Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events.
@RheumNow #ACR22 #LateBreaking
Richard Conway
Tweet
Fletcher et al. Epidemiology RA-ILD 2004-18 in VA. Incidence increased from 340 to 970/100,000PY. Prevalence increased 1.7% to 4.5%. More common males (4.81% vs 2.53%) and over 60 @RheumNow #ACR22 Abstr#1638 https://t.co/AbPgLUPoDz https://t.co/V25xDUwLbu
Richard Conway
Tweet
Askanase et al. Phase 2 RCT Cenerimod (S1P modulator) in SLE. Primary endpoint not met. Some suggestion of efficacy at highest 4mg dose. But if its already like this in a phase 2, I doubt a phase 3 will bring better results @RheumNow #ACR22 Abstr#1656 https://t.co/p4fcKW3cYD https://t.co/ha8xqeW6Xk
Julian Segan
Tweet
@RheumNow Assessing CV events in hierarchical order (each level has additional CV event). Hypothesis that increased CV events are driven by VTE in all-comers with the 10mg dose. https://t.co/IfRdJBERuA
Eric Dein
Tweet
L06 #ACR22 ORAL Surveillance Updates!
Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi
But, MACE numerically higher with Tofa w/ h/o ASCVD
Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk
Most important risk is pt's individual risks
@RheumNow https://t.co/jPPX7f5GRE
sheila
Tweet
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA:
❗Pre-conceptional NSAID use
❗Age
Thought-provoking.
Time to re-evaluate our NSAID prescribing practices for ♀️ SpA?
#ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe
sheila
Tweet
This single ctr retro cohort study by Dr ZKazmi showed ⬇️HPV vax rates & ⬆️HPV infxn rates
🔅In HPV+ pts, risk of persistent HPV infxn was similar among ♀️ aged 21-26y & 27-45y (p>0.05)
Is it time for updated cervical ca screening guidelines for #lupus?
#ACR22 @RheumNow ABST#1671 https://t.co/7Nh62EYc6Y
Mike Putman
Tweet
Interesting study (MAGICA) of withdrawing TCZ in GCA after 1 year of therapy
Comparing abrupt vs gradual discontinuation
Very important clinical quesiton; kudos to FVSG for making this happen!
#ACR22 #Vasculitis22 @RheumNow https://t.co/912GCFik6L
Richard Conway
Tweet
McCarter et al. RA patients intiating ICI. 46% risk of flare, happens quickly (27% in first 28 days) and then plateaus. Seropositive higher risk HR 1.95. No difference in mortality. @RheumNow #ACR22 Abstr#1667 https://t.co/o9SKdNAYcE https://t.co/FmN89LAggG
Eric Dein
Tweet
Ab1671 #ACR22 Cervical Cancer screening in SLE
106 SLE patients, mean age 40. Only 3.7% w HPV vax!
24% abnml PAP, 30% HPV infection
HPV highest in 21-26 yo (83%) vs 27-45 (35%)
ASCUS 50% HPV+, 1 pt squamous cell ca
Recs: HPV Vax💉, test HPV as high positivity
@RheumNow @KDAO2011 https://t.co/nHlvGVVm40
Julian Segan
Tweet
Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks.
@RheumNow #ACR22 #LateBreaking
Aurelie Najm
Tweet
Peresolimab PD-1 agonist in RA Phase 2 RCT
Primary endpoint met w/ > improvement DAS28CRP Wk12
Also greater improvement of CDAI in both treated grps
TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg
https://t.co/QtclWIWAw9
Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt
Richard Conway
Tweet
Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h
Richard Conway
Tweet
Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE than those in lowest tertile. Exacerbated by high BMI. @RheumNow #ACR22 Abstr#1634 https://t.co/T4Bx59VJPX https://t.co/oWaj9QbzgY
Mike Putman
Tweet
Important late breaker re:barriers to MTX post Roe decision
6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists
This number should be 0%!!
#ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25
sheila
Tweet
Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis
#ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC
